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INTRODUCTION 
Of all gynecological cancers ovarian malignancies represents greatest 
clinical challenge. The pathology of ovarian neoplasm is one of the most 
complex area of gynaecology because, ovaries give rise to wider variety of 
tumors than any other organ in the body.  Ovary consist of surface epithelium 
capable of mullerian differentiation, sex cells that are totipotent and 
mesenchymal cells that are multipotent. Thus ovary is complex in its 
embryology, histology and steroidogenesis and has the potential to develop 
cancer. 
In India, ovarian cancers account for about 5% of all gynaecological 
cancer. 
A women’s risk at birth of having ovarian cancer in her life is 1% to 
1.5% and that of dying from ovarian cancer almost 0.5%.  Most epithelial 
ovarian cancer in sporadic, with familial hereditary pattern accounting for 5% 
to 10% of all malignancies.  In woman with two first degree relative with 
documented premenopausal epithelial ovarian cancer, the risk of having an 
affected gene is as high a 35% to 40%. 
In women with a single first degree relative and a single second degree 
relative with epithelial ovarian cancer, the risk is two to ten fold higher. 
The tragedy of ovarian cancer is that 70% of women present with 
advanced disease.  The 5 year survival rate for stage 1 ovarian cancer is 70% 
whereas for Stage IV is 0-5%. Logically this suggest that the most productive 
way to achieve a better outcome from ovarian cancer would be to improve 
methods for earlier diagnosis  rather than to develop further heroic therapies for 
advanced disease. 
The introduction of transvaginal ultrasound has improved the ease and 
resolution of ovarian malignancy that is used to supplement a careful clinical 
examination.  As Colour Doppler has become widely available,  their potential 
value for differentiating benign from malignant tumours has increased.  
Malignant tumour often have neovascularity that consists of blood vessels with 
walls that have little or no smooth muscle support. These vessels have low 
pulsatility index and resistance index. Thus by using Doppler we can identify 
ovarian malignancy at an early stage. 
AIM OF THE STUDY 
¾ To assess the accuracy of Doppler in confirming(or) excluding the 
presence of ovarian malignancy. 
¾ To correlate Doppler findings with histopathology . 
REVIEW OF LITERATURE 
Ovarian malignancies are difficult to diagnose clinically. At the time of 
clinical diagnosis, more than 60-70% are already in stage III to IV.  If the 
gynecologist could accurately differentiate a malignant from benign mass,  
patients with masses believed to be malignant could seek proper oncologic 
consultation preoperatively and at the time of surgery the appropriate incision 
would allow careful staging. 
Ovarian neoplasm is a complex wide spectrum of neoplasm involving 
variety of histological tissue varying from epithelial tissues, connective tissue, 
specialized hormone secreting to germinal and embryonal cells. The most 
common are epithelial tumours forming 80% of all tumours.  80% are benign  
tumours and 20% malignant. Of all malignant tumours, 90% are epithelial in 
origin, 80% are primary in ovary and 20% secondary from heart, GIT and 
colon.  Benign tumours can become secondarily malignant. 
The peak incidence of invasive epithelial ovarian cancer is at 56 to 60yrs 
of age. About 30% of ovarian neoplasm’s in postmenopausal women are 
malignant, whereas only about 7%of ovarian epithelial tumor in premenopausal 
patients are malignant. The average  age  of patients with borderline tumors is 
approximately 46yrs. 
Ovarian cancer has been associated with less parity and infertility. 
Because parity is inversely related to  ovarian cancer, having at least one child 
is protective of the disease, with a risk reduction of 0.3% to 0.4%. 
Oral contraceptive use reduces the risk of epithelial ovarian cancer. 
Women who use oral contraceptives for 5 or more years reduce their relative 
risk to 0.5. 
Most epithelial ovarian cancer is sporadic with familial or hereditary 
patterns accounting for 5% to 10% of all malignancies. Hereditary ovarian 
cancers in general occur in women approximately 10years younger than those 
with non hereditary cancers. 
Most hereditary ovarian cancer is associated with germline mutations in 
BRCA1 gene; a small proportion of inherited disease is associated with 
mutations in the gene BRCA2. The mutations are inherited in an autosomal 
dominant  fashion, and therefore a full pedigree  analysis must be carefully 
evaluated. The value of prophylactic salphingooophorectomy in these patients 
has been documented. 
In the first two decades of life, almost 70% of ovarian tumours are of 
germ cell origin, and one third of these are malignant. In constrast to the 
relatively slow-growing epithelial ovarian tumours, germ cell malignancies 
grow rapidly. 
The most common types of malignant germ cell tumours are 1, 
Dysgerminomas 2, immature teratoms and 3, endodermal sinus tumours. 
Metastatic tumours to the ovaries are most frequently from breast and 
gastro intestinal tract. 
WHO CLASSIFICATION OF OVARIAN TUMOURS 
I) Common epithelial tumours 
a. Serous tumours 
b. Mucinous tumours 
c. Endometrioid tumours 
d. Clear cell (Mesonephroid tumours) 
e. Brenner tumours 
f. Mixed epithelial tumours 
g. Undifferentiated carcinoma 
h. Unclassified epithelial tumours 
 
 
 
II) Sex cord (Gonadal stromal) tumours : 
a. Granulosa – stromal cell tumours, theca cell tumours 
b. Androblastomas : Sertoli – leydig cell tumours 
c. Gynandroblastomas 
d. Unclassified 
III) Lipid (Lipoid) cell tumours 
IV) Germ cell tumours 
a. Dysgerminoma 
b. Endodermal sinus tumour 
c. Embryonal carcinoma 
d. Polyembryoma 
e. Chorio carcinoma 
f. Teratoma 
g. Mixed forms 
 
 
V) Gonadoblastoma  
a. Pure 
b. Mixed with dysgerminoma or other germ cell tumours 
VI) Soft tissue tumours not specific to ovary 
VII) Unclassified tumours 
VIII) Secondary (Metastatic) tumours 
IX) Tumour –like conditions 
BORDERLINE TUMOUR 
Borderline tumours are tumours of low malignant potential .Most 
frequently occur between the ages  of 30 to 50yrs. 
Uncommonly metastasis may occur with borderline tumour. Such 
implants have been divided into noninvasive and invasive forms. 
Criteria for the diagnosis of borderline tumours are as follows: 
1. Epithelial hyperplasia in the form of pseudo stratification, tufting, 
cribriform and micropapillary architecture. 
2. Nuclear atypia and increased mitotic activity. 
3.  Detached cell clusters. 
4. Absence of destructive stromal invasion. 
It should be emphasized that about 20%to 25% of borderline tumours 
spread beyond the ovary. The diagnosis of borderline tumor versus malignant 
ovarian tumour must be based on the histological features of the primary 
tumour. 
EPITHELIAL OVARIAN CANCER 
Approximately 90% of ovarian cancers are derived from tissues that 
come from the coelomic epithelium or mesothelium. The cells are a product of 
the primitive mesoderm  which can undergo metaplasia. Neoplastic 
transformation can occur when the cells are generally predisposed to 
oncogenesis or exposed to an oncogenic agent or both. 
SEROUS CYSTADENOMA AND CYSTADENOCARCINOMA 
• Most  common of cystic ovarian neoplasm.  
• Constitutes 50% of all ovarian neoplasms of mucinous tumours 60% 
benign, 15% Borderline and 25% malignant tumours.   
• Half of the case is bilateral.   
• Occur in third, fourth and fifth decade of life. 
• Histology resembles endosalphinx 
• Serous tumours develop by invagination of the surface ovarian epithelium 
and are so classified because they secrete serous fluid. 
Border line serous tumours: 
 Approximately 10%of  all ovarian serous tumours fall in to the category 
of a tumour of low malignant potential and 50% occur before the age of 40yrs. 
10% of women with ovarian serous borderline tumours have extra 
ovarian implants. 
In malignant serous tumours, stromal invasion is present. 
Laminated, calcified psammoma bodies are found in 80% of serous 
carcinomas. 
Serous psammoma carcinoma is a rare variant of serous carcinoma 
characterized by massive psammoma body formation and low grade 
cytological features. 
MUCINOUS TUMOURS 
• Can grow to large size. 
• Represent 8 to 10 % of epithelial tumours. 
• Essentially benign. 5% to 10% become malignant. 
• Usually unilateral, 5% are bilateral. 
• Occur in women between 30 to 60 years. 
• Histology resemble endocervix. 
• These cystic ovarian tumours have  mucin secreting epithelium. 
• Borderline Mucinous tumor: 
• The mucinous tumours of low malignant potential is a diagnosis difficult to 
make. 
Frequently, well differentiated mucinous epithelium may be seen 
immediately adjacent to  a poorly differentiated focus.  Therefore, it is 
important to make multiple sections from many areas in the mucinous tumour 
to identify the most malignant alteration. 
Pseudomyxoma Peritonei: 
It is clinical term used to describe the finding of abundant mucoid  or 
gelatinous material in the pelvis and abdominal cavity surrounded by fibrous 
tissue. 
ENDOMETRIOID TUMOURS 
• Accounts for 6-8% of epithelial tumours. 
• Histology resembles endometrium. 
• Borderline endometrioid tumour of low malignant potential has a wide 
morphologic spectrum.  Tumour may resemble an endometrial polyp or 
complex endometrial hyperplasia with glandular crowding. 
• Multifocal disease – Endometrioid carcinoma of the ovary is associated in 
15% to 20% of the cases with carcinoma of the endometrium. 
CLEAR CELL TUMOURS 
• Less than 1% of epithelial lesions. 
• Highly malignant. 
• Histology made of CLEAR CELL AND HOB NAIL CELLS. 
• Focal areas of endometriosis and endometrioid carcinoma sometimes occur. 
• Almost invariably high grade (Grade 3) nuclei are identified.  Hence, clear 
cell carcinoma is not graded. 
BRENNER TUMOURS 
• Less than 1% of epithelial tumours. 
• Rarely becomes malignant. 
• Characteristic histology – WALTHARD CELL NEST. 
NONEPITHELIAL OVARIAN CANCERS 
Nonepithelial malignancies of the ovary account for about 10% of all 
ovarian cancers.  Nonepithelial ovarian cancers include malignancies of germ 
cell origin, sex-cord stromal cell origin, metastatic carcinomas to the ovary and 
a variety of extremely rare ovarian carcinoma (eg. sarcoma lipoid cell 
tumours). 
GERM CELL TUMOURS 
Germ cell tumours derived from the primordial germ cells of the ovary. 
Although 20% to 25%  of all benign and malignant ovarian neoplasms 
are of germ cell origin, only about 3% of these tumours are malignant.   
In the first two decades of life, almost 70% of ovarian tumours  are of 
germ cell origin, and one third of these are malignant. 
 
DYSGERMINOMA 
• Mot common malignant germ cell tumour – 30% - 40% of ovarian 
cancers of germ cell origin. 
• Dysgerminoma represent only 1% to 3% of all ovarian cancers, but they 
represent 5% to 10% of ovarian cancers in patients younger than 20yrs. 
• 75% of cases occur between 10 & 30 years. 
• Malignancy rate 30-50%. 
• 20 to 30% ovarian malignancy associated with pregnancy are 
dysgerminoma. 
• Dysgerminoma are found in both sexes and may arise in gonadal or 
extragonadal sites. 
Approximately 5% of dysgerminomas are discovered in phenotypic 
women with abnormal gonads. This malignancy can be associated with patients 
who have pure gonadal dysgenesis, mixed gonadal dysgenesis and the 
androgen insensitivity syndrome. Therefore for premenarcheal patients with a 
pelvic mass, the karyotype should be determined. 
Dysgerminoma is bilateral in 10-15% of cases.  Dysgerminoma is the 
only germ cell malignancy that has this significant rate  of bilaterality. 
ENDODERMAL SINUS TUMOUR 
• Also known as Yolk Sac carcinoma because they are derived from primitive 
yolk sac. 
• Third frequent malignant germ cell tumour. 
• Median age 16-18 yrs, 1/3rd of patients are premenarcheal. 
• 100% unilateral. 
• Characteristic histology – SCHILLER DUVAL BODY. 
Abdominal or pelvic pain is the most frequent initial symptom, occuring 
in about 75% of patients, whereas an asymptomatic pelvic mass is documented 
in 10% of patients. 
Endodermal sinus tumour associated with gonadal dysgenesis and so 
chromosomal analysis should be performed preoperatively. 
Most Endodermal sinus tumour lesions secrete Alpha Fetoprotein and rarely 
may elaborate α1 Antitrypsin. 
EMBRYONAL CARCINOMA 
• Extremely rare tumour. 
• Age : 4-28 yrs. 
• Embryonal carcinoma distinguished from a choriocarcinoma of the ovary 
by the absence of syncytiotrophoblastic and cytotrophoblatic cells. 
• Embryonal carcinoma may secrete estrogens. Patient exhibits symptoms 
and signs of precocious pseudopuberty or irregular bleeding. 
• Embryonal carcinoma frequently secrete Alpha fetoprotein and Human 
chorionic gonadotrophin. 
POLYEMBRYOMA 
• Extremely rare tumour 
• Occur in very young, premenarcheal girls 
• Characteristic histology : EMBRYOID BODIES 
CHORIOCARCINOMA 
• Extremely rare. 
• Most occur in patients younger than 20 yrs. 
IMMATURE TERATOMA 
• Accounts for <1% of all ovarian cancer. 
• 2nd most common germ cell malignancy. 
• 50% occur in women between 10 and 20 yrs. 
• Immature teratomas contain elements that resemble tissue derived from the 
embryo. 
• The prognosis can be correlated with the grade determined by the quantity 
of the immature neural elements.  With a higher grade there is a poorer 
prognosis. 
• Malignant changes in  benign cystic teratomas has been recorded as 
occurring in 0.5 to 2% of cases, usually in patients older than 40 years of 
age. 
MIXED GERM CELL TUMOUR 
• Contain two or more elements of lesion of above described germ cell types. 
• Most frequent combination : dysgerminoma and endodermal sinus tumours. 
• The most important prognostic features are the size of the primary tumour 
and the relative size of its most malignant component. 
GRANULOSA CELL TUMOUR 
• Granulosa stromal cell tumours include granulosa cell tumours,  thecomas 
and fibromas. 
• Only in 2% bilateral. 
• Found in women throughout reproductive and postmenopausal years. Found 
in prepubertal in 5% of cases. 
• Secrete estrogen. 
• Characteristic histology  CALL EXNER BODIES- 
Granulosa cells show a tendency to arrange themselves in small clusters 
or rosettes around a central cavity, so there is a resemblance to primordial 
follicle. In prepubertal  lesions, 75% are associated with sexual 
pseudoprecocity because of estrogen secretion. 
SEX CORD STROMAL TUMOURS 
• Sex- cord stromal tumours of the ovary account for about 5% to 8% of all 
ovarian malignancies . 
• Sex cord stromal tumours are derived from  the sex cords and the ovarian 
stroma or mesenchyme. 
SERTOLI LEYDIG CELL TUMOUR 
• Occur in 3rd & 4th decade of life. 
• Extremely rare and account for less than 0.2% of ovarian cancer. 
• Produce androgen – clinical virilization in 70% to 85% of patient. 
• <1% Bilaterality  
METASTATIC TUMOURS 
About 5% to6% of ovarian tumors are metastatic  from the organs most 
frequently from the female genital tract, the breast or  the gastrointestinal tract. 
The metastases may occur from direct extension of another pelvic neoplasm, by 
hematogenous or lymphatic spread or by  transcoelomic dissemination ,with 
surface implantation of tumor that spread in the peritoneal cavity. 
KRUKENBERG TUMOUR 
• Krukenberg tumour account for 30% to 40% of metastatic cancer to ovaries. 
• Primary frequently in stomach less commonly in colon, breast or biliary 
tract.  
• Usually bilateral. 
• Characteristic histology : SIGNET RING CELLS. 
PROGNOSTIC VARIABLES IN EARLY STAGE EPITHELIAL 
OVARIAN CANCER 
 
LOW RISK HIGH RISK 
Low grade High grade 
Non clear histologic type Clear  cell Histologic type 
Intact capsule tumor growth through capsule 
No surface excrescences Surface  excrescences 
No ascites ascites 
Negative peritoneal cytologic  
findings 
Malignant cells in fluid 
Unruptured or intraoperative 
rupture 
Preoperative  rupture 
No Dense adherence Dense adherence 
Diploid Tumor Aneuploid 
 
 FIGO STAGING OF OVARIAN CARCINOMA  
STAGE I : Tumour restricted to one or both ovaries. 
1A  : Tumour restricted to one ovary. No tumour on external surface, capsule 
intact, no malignant ascites. 
1B : Tumour restricted to both ovaries. No tumour on external surface, capsule 
intact, no malignant ascites. 
IC : Tumour IA or IB, but with tumour on the surface of one or both ovaries or 
with  capsule ruptured,  or with malignant ascites or positive peritoneal  
washings. 
STAGE II : Tumour involves one or both ovaries with pelvic extension. 
IIA : Extension and/or  Metastasis to  the uterus and / or fallopian  tubes.  No 
malignant cells in ascites / washings. 
IIB : Extension to other pelvic organs. No malignant cells in ascites or 
washings. 
IIC : Tumour IIA or IIB with surface growth; or with capsule ruptured at /or 
prior to surgery; or with  malignant ascites or with positive peritoneal 
washings. 
STAGE III : Tumour involving one or both ovaries, with microscopic implants 
outside the pelvis and / or positive nodes (inguinal, retroperitoneal). Tumour 
limited to true pelvis but with histological evidence of spread to bowel, 
omentum, presence of superficial metastases on the liver. 
IIIA : Tumour grossly limited to the pelvis, nodes negative, but microscopic 
seeding of peritoneum. 
IIIB : Tumour with abdominal peritoneal implants of less than 2cm size and 
nodes negative. 
IIIC : Peritoneal implants of more than 2 cm size and / or positive nodes. 
STAGE IV : Growth involving one or both ovaries with distant metastases in 
liver, lungs and pleura.  If  pleural effusion is present, there must be positive 
cytologic test  results to allot a case to stage IV. Parenchymal liver metastasis 
equals to stage IV.   
COMPARISON OF FIGO STAGING AND 5YRS SURVIVAL 
 Stage 0 - 90-100% 
 Stage 1 - 70% 
 Stage 2 - 25-30% 
 Stage 3 - 10%    
 Stage 4 - 0-5% 
GENETIC RISK FOR EPITHELIAL OVARIAN CANCER 
The risk of ovarian  cancer is higher than that in the general population 
in women with certain family histories. Most epithelial ovarian cancer is 
sporadic, with familial or hereditary patterns accounting for 5% to 10% of all 
malignancies. 
ROLE OF CA 125 
Ca 125 is a glycoprotein present in 80% of non mucinous tumour. Ca 
125 is also increased in inflammatory condition of the abdomen, liver disease, 
recent surgery and benign gynaecologic conditions such as fibroids, 
endometriosis, ectopic pregnancy or a ruptured cyst. 
Ca 125 is used during course of diagnosis, treatment and follow up of 
ovarian and other closely related cancers, such as primary peritoneal and 
fallopian tube cancer. 
Normal value ranges from 0 to 35 U/ml. Using 35 as cut off value, 
identifies 50% of stage I ovarian cancer but 80% of stage II,III and IV 
HEREDITARY OVARIAN CANCER 
BRCA1and BRCA2 
Most hereditary ovarian cancer is associated with mutations in the 
BRCA1 gene, located on chromosome 17. A small proportion of inherited 
disease is associated with germ line mutations in another gene, BRCA2, 
located on chromosome 13.    
There is a higher- than- expected risk of ovarian and endometrial cancer 
in the Lynch II syndrome, known also as the hereditary nonpolyposis colorectal 
cancer syndrome (HNPCC syndrome).  
The mutations are inherited in an autosomal dominant fashion and 
therefore a full pedigree analysis (i.e., both maternal and paternal sides of the 
family) must be carefully evaluated.  
Based on analysis of women who have a mutation in the BRCA1 gene 
and are from high-risk families, the lifetime risk of ovarian cancer may be as 
high as 28%  to 44% , and the risk has been calculated to be as high as 27% for 
those women with BRCA2 mutation. The risk of breast cancer in women with a 
BRCA1or BRCA2 mutation may be as high as 56% to 87%. 
Hereditary ovarian cancers in general occur in women approximately 
10years younger than those with nonhereditary tumours. 
PEDIGREE ANALYSIS 
The risk of carrying a germ line mutation that predisposes to ovarian 
cancer depends on the number of first-and/or second- degree relatives (or both) 
with a history of epithelial ovarian  carcinoma or breast cancer (or both) , and 
on the number of malignancies that occur at an earlier age. The degree of risk is 
difficult to determine precisely unless a full pedigree analysis is performed. 
• In families with two  first- degree relatives(i.e., mother, sister, or daughter) 
with documented premenopausal epithelial ovarian cancer, the risk that a 
female first- degree relative has an affected gene could be as high as 35% to 
45%. 
• In families with a single  first-degree relative and a single second-degree 
relative with epithelial ovarian cancer, the risk that a woman has an affected 
gene also may be increased. The risk may be two to 10 fold higher than in 
those without a familial history of the disease. 
• In families with a single postmenopausal first-degree  relative with 
epithelial ovarian carcinoma, a women may not have an increased risk of 
having an  affected gene because the case is most likely  to be sporadic. 
However, if the ovarian cancer occurs in a premenopausal relative, this 
could be significant and a full pedigree analysis should be undertaken. 
• Women with a primary history of breast cancer have twice the expected  
incidence of subsequent ovarian cancer.  
 
HEREDITARY NONPOLYPOSIS COLON CANCER, OR LYNCH  II 
SYNDROME 
 
HNPCC syndrome, which includes multiple adenocarcinomas involves a 
combination of familial colon cancer (known as the lynch I syndrome); a high 
rate of ovarian endometrial, breast cancers and other malignancies of the 
gastrointestinal and gentiourinary systems. The mutations that have been 
associated with this syndrome are MSH2, MLH1, PMS1,and PMS2. 
 
CLINICAL FEATURES OF BENIGN TUMOURS 
Symptoms 
Most tumors are asymptomatic. These are detected accidentally. 
However the patient may present the following symptoms. 
1. Heaviness, in the lower abdomen. 
2. A gradually increasing mass in lower abdomen.  
3. Dull aching pain in lower abdomen. 
4. In neglected cases, the tumour may be big enough to fill whole of the 
abdomen. It then produces cardio respiratory embarrassment or 
gastrointestinal symptoms like nausea or indigestion. 
5. Menstrual pattern remains unaffected unless associated with hormone 
producing tumours  menorrhagia or postmenopausal  bleeding or precocious 
puberty in feminizing tumour.  
Signs 
• General condition remains unaffected, However, in huge mucinous 
cystadenoma, the patient may be cachectic due to protein loss . 
• Pitting odema of legs may be present when a huge tumour presses on the  
great veins. 
 
ABDOMINAL EXAMINATION 
An ovarian tumour which is enlarged sufficiently so as to occupy the 
lower abdomen presents with the following. 
 
INSPECTION 
There is a mass of the lower abdomen over which the abdominal wall 
moves freely with respiration. The mass may be placed centrally or in one side 
. At times, the mass fills the entire abdominal cavity.  The flanks remain flat . 
 
PALPATION 
 Feel is cystic or tense cystic. Benign solid tumours such as fibroma, 
thecoma, Brenner tumour are rare. 
 Freely mobile from side to side but restricted from above down wards 
unless the pedicle is long. Too big a tumour or adhesions make its mobility 
restricted. 
 Upper and lateral borders are well defined but the lower pole is difficult to 
reach suggestive of pelvic origin . However, with long pedicle, the tumor 
may be displaced upwards so as to reach the lower pole. 
 It is usually not tender. 
PERCUSSION 
Percussion note is dull in the centre and resonant in the flanks . A fluid 
thrill may be elicited when the walls are thin and the content is watery. Co-
existing ascites may be present even in a benign solid tumour (fibroma) and is 
called Meigs syndrome. 
MEIGS SYNDROME 
Ascites and right side hydrothorax in association with fibroma of the 
ovary, Brenner,thecoma and granulosa cell tumour is called Meigs syndrome. 
Ascites and hydrothorax when present in conditions other than those mentioned 
are called pseudo-Meigs syndrome. 
AUSCULATION 
A friction rub ,may be present over the tumour . 
PELVIC EXAMINATION 
Bimanual examination reveals 
• The uterus is separated from the mass. 
• A groove is felt between the uterus and the mass. 
•  Movement  of the mass per abdomen fails to move the cervix. 
• On elevation of the mass per abdomen , the cervix remains in stationary 
position. 
The lower pole  of the cyst can be felt through the fornix.  
CLINICAL FEATURES OF OVARIAN CANCER 
Symptoms 
The majority of women with epithelial ovarian cancer have  vague and 
nonspecific symptoms.  In early- stage disease, the patient may experience 
irregular menses if she is premenopausal. If a pelvic mass is compressing the 
bladder or rectum, she may report urinary frequency or constipation, 
occasionally, she may perceive lower abdominal distention, pressure, or pain 
such as dyspareunia. Acute symptoms, such as pain secondary to rupture or 
torsion are unusual. 
In advanced- stage disease , patients most often have symptoms related 
to the presence of ascites , omental   metastases or bowel metastases. The 
symptoms include abdominal distention, bloating, constipation, nausea, 
anorexia , or early satiety. Premenopausal women may report irregular or 
heavy menses, whereas vaginal bleeding may occur in post-menopausal 
women. 
Signs 
The most important sign of epithelial ovarian cancer is the presence of 
pelvic mass on physical examination. A solid, irregular, fixed pelvic mass is 
highly suggestive of an ovarian malignancy. If, in addition, ascites is present, 
the diagnosis of ovarian cancer is almost certain. 
The evaluation for adnexal masses include history, physical 
examination, USG and Doppler. 
Doppler study were based on discovery of natural phenomenon 
“Doppler effect” which dates back to 20th century. The phenomenon bears 
name of its discoverer Christian Andrews Doppler, an Australian 
mathematician and Physicist. Another critical event was discovery of 
piezoelectric phenomenon by Pierre curie, Jacques curie which enabled the 
development of ultrasonic transducers many decades later. 
PHYSICAL PRINCIPLE OF DOPPLER ULTRASONOGRAPHY 
Sound is a form of mechanical energy that travels through solid or liquid 
media as pressure waves.  Sound waves are generated when a object vibrates in 
a medium. Sound waves from a vibratory source or from a reflector move 
across surfaces of high or low pressure.  These surfaces are called waveforms.  
The shape of waveform depends on the shape of the source or the interface.  
With Doppler ultrasonics, the scattered waveform is spherical as RBC’s behave 
as spherical sources during the scattering of an incident beam. 
The propagation of sound in a medium is the rate of change of position 
of the sound wave in unit time in that medium.  It is called velocity when the 
direction of motion is also specified.  The frequency of sound is the number of 
cycles occurring in one second.  One cycle is called a hertz (Hz). 
Audible sound frequency ranges from approximately 10Hz to 20KHz.  
Sound with a frequency of more than 20Khz  inaudible to the human ear and is 
known as ultrasound.  With Doppler ultrasound used for medical diagnosis the 
commonly employed frequency range is 2-10 Mhz. 
To produce oscillation or vibrations at the rate of millions of cycle per 
second, special material with piezoelectric properties are used.  These 
piezoelectric elements are solid non-conducting substances that demonstrate 
physical properties whose measurements are different along different axis. 
When compressed in certain direction, these elements undergo electric 
polarization and a corresponding voltage is generated that is proportional to the 
pressure. Conversely when such a element is subjected to an electric field it 
exhibits mechanical distortion by an amount proportional  to the applied field.  
This phenomenon is known as piezoelectric effect and allows interconversion 
between sound and electricity and form the basis for the construction of 
Doppler and other types of ultrasound transducers. 
DOPPLER STUDIES 
Doppler velocimetry is a nonvasive technology that uses high frequency 
sound waves for the investigations of blood flow.  It yields a wide spectrum of 
hemodynamic information. Doppler study is based on “Doppler Effect”1 
 
 
 
Doppler effect is as follows ,  
“When a high frequency sound wave (Ultrasound) is directed toward a 
moving target, the back scattered sound wave will have a different frequency 
than the emitted sound.  The magnitude  of this frequency shift is proportional 
to the  velocity of the moving target from which it is reflected. When an 
ultrasound beam is directed towards a blood vessel, the sound wave is mainly 
reflected by red blood cells, which flow in it. This is the basis for the use of 
Doppler technology in the assessment of blood flow parameters. 
In Doppler colour flow mapping, two dimensional flow patterns are 
superimposed on anatomic images in real time.  The flow patterns are derived 
from the mean frequency shift using signal processing technique. Flow towards 
transducer is red and flow away from it is blue. 
Doppler is generally used in two ways to estimate circulatory 
hemodynamics. 
1) Direct measurement of volume of blood flow 
2) Indirect measurement of flow velocity using waveform analysis. 
The relationship between blood flow velocity and the Doppler frequency shift 
is determined by a complex interplay of multiple factors. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
The following velocity indices were measured 
Resistance index (R1)=Peak systolic velocity – end diastolic velocity 
        Peak systolic Velocity 
Pourcelol (1974) First reported this index and also called pourcelol 
index 
 
Pulsatility Index =Peak systolic velocity – End diastolic velocity 
Mean Velocity 
 
Gosling & King (1976) Were first to putforth pulsatility index. 
Pulsatility index is a measure of the impedance to blood flow, a low 
value indicating decreased impedance and a high value increased impedance to 
blood flow.  
Experimental studies suggest that the development of new blood vessel 
is necessary to sustain the growth, invasion and metastasis of tumours.  
Induction of angiogenesis is mediated by a number of angiogenic peptides such 
as vascular  endothelial growth factor and platelet derived endothelial cell 
growth factors. These two factors are associated with an increase in 
microvessel density.  The newly formed vessels are large capillaries or 
sinusoids and do not contain smooth muscle in their walls but only fibrous 
connective tissue.  Their basement membrane is markedly reduced and their 
permeability is increased.  For these reasons, the neoangiogeneic vessels have 
low impedance as reflected by blood flow parameters. 
The first medical application of Doppler sonography were initiated 
during the late 1950. Shigeo satomura from the Institute of scientific and 
industrial research of Osaka University in Japan developed the first Doppler 
ultrasound for Medical Diagnostic purpose. 
Sonography for ovarian screening was first proposed by Campbell et 
al3,4. These investigators noticed a high correlation co-efficient between 
ovarian volumes calculated with abdominal sonography and the real volume 
calculated after oophorectomy.3,4 Studies comparing abdominal and 
transvaginal sonography concluded that the transvaginal sonography provided 
better information regarding ovarian morphological characteristics and size 
because of the higher frequency probes used and their proximity to the gonad.5  
When compared with macroscopic examination of a tumour, transvaginal 
sonography was found to characterize tumour morphologic characteristics, 
correctly in 96% of cases.6 
Since 1980, Colour Doppler sonography has been used as an additional 
tool for differential diagnosis of ovarian tumours because this diagnostic 
techniques provides indirect information on metabolism and direct information 
on the vascular anatomy of the organ. 
Bourne et al7 (1989) published their novel finding that they could 
differentiate between primary ovarian cancer and many benign pelvic masses 
with transvaginal colour flow ultrasonography.  Evidence of neovascularisation 
was sought in the masses and the vascular permeability index was calculated.  
Lack of neovascularisation and a high pulsatility index were able to exclude the 
presence of invasive primary ovarian cancer.  Folkman et al8(1989)had shown 
that angiogenic activity precedes the development of tumour in hyperplastic 
pancreatic islets in transgenic mice. 
Kurjak et al9 (1992)calculated prospectively the resistance index for 743 
(74%) of 1000 postmenopausal women. The sensitivity and specificity of the 
resistance index in distinguishing  benign masses from malignant were 96% 
and 95% respectively; the positive predictive value and negative predictive 
value were also 96% and 95% respectively. 
Kurjak et al10 (1993)described 18 cases of stage 1 ovarian cancer 
detected by transvaginal sonography using colour Doppler imaging, 2 of which 
had a normal B mode appearance. 
Weiner et al11(1992) concluded that use of Doppler technology may 
reduce the rate of false positive results seen with transvaginal sonography or 
transabdominal sonography. 
Zanetta et al12 (2002)reported a 77 year old woman who had normal 
shaped ovaries with low resistance blood flow. Although  there was suspicion 
of cancer, no surgical procedure was performed and patient was followed up 
with serial measurements of CA 125.  One year later, pelvic sonography 
revealed an enlarged ovary and an increase in CA 125 level .Laporotomy was 
then carried out, and the intraoperative findings were compatible with stage III 
ovarian Cancer. 
Daskalakis et al13 (2004)used resistance index for evaluating character 
of the tumour and found the sensitivity, specificity, positive predictive value 
and negative predictive value to be 87.5%, 91.2%, 70% and 96.9% 
respectively. 
Fleischer et al14 (1996)concluded that transvaginal colour Doppler 
ultrasonography is capable of early detection of ovarian carcinoma.  An 
improved detection rate may be realised with better identification of high risk 
patients who should be studied with transvaginal colour Doppler 
ultrasonography. 
Rampone etal15 (2001)concluded that colour Doppler ultrasonography is 
a valid method of  screening at the first level as it is  non invasive, painless and 
therefore well accepted by the patient. 
From these studies it is clear that transvaginal  Doppler waveforms 
demonstrate high diastolic flow or low resistance patterns in case of ovarian 
malignancy.  This is due to the decreased muscle contractility of the newly 
formed blood vessels which leads to an increased flow in diastole and increased 
arteriovenous shunting.  New advances are providing evidence that 
transvaginal Doppler ultrasound is a new and potentially adjuvant technique to 
differentiate benign from malignant  ovarian tumours, particularly those 
tumours that possess ultrasonographic features suggestive of malignancy. 
 
RECOMMENDATIONS 
Current recommendations for management of women at high risk for 
ovarian cancer are summarized as follows. 
1. Women who appear to be high risk for ovarian or breast cancer should 
undergo genetic counseling and, if the risk appears to be substantial, 
may be offered genetic testing for BRCA1 and BRCA2. 
2. Oral contraceptives should be recommended to young women before 
they embark on an attempt to have a family. 
3. Women who don’t wish to maintain their fertility or who have 
completed their families should be recommended to undergo 
prophylactic bilateral salphingo- oophorectomy. The risk should be 
clearly documented, preferably established by BRCA1and 
BRCA2testing, before oophorectomy is performed . This women should 
be counselled that this operation does not  offer absolute protection, 
because peritoneal carcinomas occasionally can    occur after bilateral 
oophorectomy.  
 4. In women who also have a strong family history of breast or ovarian  
cancer, annual mammography screening should be performed beginning at 
age 30years. 
5. Women with a documented HNPCC syndrome should be treated as above 
but in addition, they should undergo periodic screening mammography, 
colonoscopy, and endometrial biopsy. 
NEWER APPROACHES 
A new approach is the use of proteomic patterns to identify ovarian 
cancer using surface- enhanced laser desorption ionization time-of –flight 
(SELDI –TOF)Technology. In a study using this technology, the sensitivity for 
predicting ovarian cancer was 100% with a specificity of 95% and a positive 
predictive value of 94%. This techonology is in early  phases of development 
and validation and its efficacy has yet to be demonstrated in large population – 
based studies. 
Another new approach is the measurement of plasma DNA levels and 
allelic imbalance by a technique known as digital single nucleotide 
polymorphism (SNP) analysis. In a study by Chang  et al55 (2002)this analysis 
had a 87% positive correlation in stages I and II patients, and a 95%  
correlation in patients with stages III and IV disease. 
MATERIALS AND METHODS 
Study Design  
Prospective study 
Period of Study 
August 2006 – August 2007 
Place of Study 
Govt. RSRM lying-in Hospital, Chennai.  
Case Selection 
50 cases of ovarian tumours who got admitted at Government RSRM 
Hospital, Chennai – 13 were recruited in the study. 
Inclusion Criteria 
Age 14-70 yrs 
Premenarcheal ovarian tumour > 2cm 
Premenopausal > 6cm size of tumour 
Postmenopausal >8.8ml volume of ovary. 
Exclusion Criteria 
Age <1 4 years or > 35 years 
Premenopausal < 6cm size of tumour 
Methods of Study 
Besides routine investigations all the patients were subjected to 
ultrasonography.  Doppler was done prior to surgery.  Doppler signals were 
obtained within the whole tumour area, including the capsule of the tumour. 
Vasularisation was evaluated as absent if no Doppler frequency shift was found 
in the tumour. 
From the peak systolic velocity and end diastolic velocity, pulsatility 
index and resistance index were computed electronically. 
 
Resistance index  = Peak systolic velocity – End diastolic velocity 
    Peak systolic velocity 
 
Pulsatility index = Peak systolic velocity – End diastolic velocity 
    Mean velocity  
 
Laporotomy was done.  All the materials removed after Laporotomy was 
subjected to histopathological examination.  Postoperative histopathological 
picture was correlated with Doppler and diagnostic accuracy was evaluated. 
Sensitivity, specificity, positive predictive value and negative predictive 
value were calculated. 
RESULTS 
Patients age in the study group ranged from 14-67 years. Out of 50 
patients studied.  10 were nulliparous and 9 were postmenopausal. 
In the study group 13 patients were diagnosed as having malignant 
tumour and 36 cases were diagnosed as having benign tumours by Doppler.   
One patient  had resistance index of 0.47 and pulsatility index of 0.67, 
histopathology showed borderline tumour. 
Out of 50 cases included in study, one patient turned out to have 
borderline tumour by histopathology.  Out of the  remaining 49 cases 12 cases 
turned out to be malignant and 37 cases as benign by histopathology. 
TABLE – 1  
                    HPE 
Doppler          
Malignant Benign 
Malignant 11 2 
Benign 1 35 
True positive   : 11 
True negative  : 35 
False positive   : 2 
False negative  : 1 
Sensitivity   : 91.7% 
Specificity   : 94.6% 
Positive predictive value : 84.6% 
Negative predictive value  : 97.2% 
 
 
 
TABLE - 2 
HISTOPATHOLOGICAL DIAGNOSIS 
 
 Benign Tumours No. 
1) Serous cystadenoma 24 
2) Mucinous cystadenoma 8 
3) Benign cystic teratoma 4 
4) Chocolate cyst 1 
 Malignant tumours  
1) Serous cystadenocarcinoma 7 
2) Mucinous cystadenocarcinoma 1 
3) Granulosa  cell tumour 1 
4) Yolk Sac Tumour 1 
5) Dysgerminoma 1 
6) Krukenberg 1 
 Borderline 1 
 
TABLE - 3 
AGE DISTRIBUTION OF BENIGN & MALIGNANT  
OVARIAN TUMOURS 
 
Benign Malignant Age 
No. % No. % 
Type of Malignancy 
< 20 yrs 3 6.1% 2 4.1% Yolk Sac tumour,  
Dysgerminoma, 
21-30 yrs 14 29% 1 2% Krukenberg Tumour 
31-40 yrs 7 14.3% 2 4.1% Granulosa cell tumour 
Serous papillary           
cystadenocarcinoma 
41-50 yrs 10 20% 1 2% Serous papillary    
cystadenocarcinoma 
Above 50 
yrs 
3 6.1% 6 12.2% (5) serous cystadenocarcinoma 
(1) Mucinous cystadenocarcinoma 
Most common benign tumour – serous cystadenoma. 
Most common malignant tumours – serous cystadenocarcinoma. 
INTERPRETATION OF BENIGN LESIONS 
The criteria used for diagnosing benign tumour using resistance index 
and pulsatility index were > 0.42 and > 1 respectively in my study. When 
resistance index and pulsatility index were >0.42 and >1 respectively, Doppler 
is of high resistance flow. 
The criteria used for diagnosing malignant tumour using resistance 
index and pulsatility index were < 0.42  and < 1 respectively in my study. 
When resistance index and pulsatility index were < 0.42 and <1 respectively, 
doppler is of low resistance flow. 
Tumour with no vascularity are included in benign tumour. 
 
 
TABLE - 4. 
Age   Nature of 
Tumour 
Benign Malignant 
<50yrs 34 6 
>50yrs 3 6 
P= <0.0001 
Malignant tumour is more common in >50yrs of age 
 
Table - 5 
BENIGN  OVARIANS TUMOURS 
Type of Benign tumors Percentages 
Benign Serous cytadenoma 65% 
Mucinous cystadenoma 21% 
Dermoid Tumours 11% 
Chocolate cyst 3% 
 
Benign serous cystadenoma is the most common benign tumour 
followed by Mucinous. 
 
TABLE - 6 
MALIGNANT OVARIAN TUMOURS 
Malignant ovarian tumors Percentages 
Serous cystadesocaicinoma  58.3% 
Mucinous cystadenocarcinoma 8.3% 
Granulsa cell tumour 8.3% 
Yolksac tumour 8.3% 
Dysyerminoma 8.3% 
Krukenberg 8.3% 
 
Serous cystadenocarcinoma is the most common malignant tumour 
TABLE - 7 
STAGING OF OVARIAN CANCER 
Stage of Ovarian cases Percentages 
Stage 1 8% 
Stage 2 17% 
Stage 3 50% 
Stage 4 25% 
 
Most  of ovarian tumours are in advanced stage. 50% of cases in stage 3. 
 
TABLE - 8. 
TYPES OF OVARIAN TUMOUR 
Types of tumour Percentages 
Benign  74% 
Malignant 24% 
Border line 2% 
 
Malignant tumour constitutes roughly ¼ th  of ovarian tumours 
 
TABLE - 9 
COMPLAINTS & NUMBER OF PATIENTS. 
Complaints Number of patients. 
Pain Abdomen 38 
Abdomen Distension 16 
Menstrual disturbance  8 
Vomiting 3 
Pressure Symptom 1 
 
DISCUSSION 
The incidence of ovarian tumour 4.4%. 
The sensitivity, specificity, positive predictive value and negative 
predictive value of Doppler in diagnosing ovarian was 91.7%, 94.6%, 84.6% 
and 97.2% respectively in my study.  This was similar to the study by 
Daskalakis et al, 2004. 
 
COMPARISON OF DOPPLER STUDY IN OVARIAN TUMOUR 
 
 Sensitivity Specificity PPV NPV 
Weiner et al (1992)11 94% 97%   
Sawicki et al (1995)17 100% 94% 85% 100% 
Merce et al (1998)18 80% 66.7% 33% 94% 
Fleischer et al (1991)19   100% 73% 
Daskalakis et al 2004)13 87.5% 91.2% 70% 96.9% 
Alcazar et al (2001)20 88% 91% 79% 95% 
Zanetta et al (1994)21 85% 91% 89%  
Timor Trisch et al (1993)22 94% 99% 94%  
Krzysztof et al (2003)23 100% 61.3% 69.2%  
Our study (2007) 91.7% 94.6% 84.6% 97.2% 
 
1) Mean RI & PI 
Mean R1 & PI for benign tumours 0.69 & 3.325. 
Mean R1 & PI for malignant tumours 0.39 & 0.80 
2) Age Distribution 
 Patients age in the study group ranged from 14-67 yrs. 
 Both Germ cell tumour occurred in < 20 yrs. 
 Most epithelial tumour occurred in > 50 yrs (Table 3) 
Most of ovarian malignancy occurred in above 50 yrs age group with a 
probability of < 0.0001(Table 4) 
 3) Type of Tumour 
 Most common Benign tumour – serous cystadenoma (Table 5) 
 Malignant tumour – serous cystadeno carcinoma(Table 6) 
Benign and malignant epithelial tumour constitutes 80% of  which 
benign and malignant serous tumour constitutes 77.5%. 
 Benign ovarian tumour constitutes 74%, Malignant tumours 24% and 
borderline tumour 2%.(Table 8) 
Staging of Ovarian Cancer (Table 7) 
Most of the cases included in my study were in advanced stage of 
cancer. 
Stage 1-8% 
Stage 2-17% 
Stage 3-50% 
Stage 4 – 25% 
This may be due to asymptomatic nature of disease. 
Complaints : (Table. 9) 
Most common complaints – abdominal pain . 
 
• Prediction of histological type is not possible with Doppler 
• To improve diagnostic accuracy of  Doppler ultasonography it can be 
combined with CT and MRI. 
• Main advantage of Doppler is its low cost and absence of radiation when 
compared with CT.  It can therefore be used safely in all cases. 
• Main disadvantage is that it is operator dependent and depends on the 
operator’s expertise as well as the resolution of the device used. 
• It narrows the wider differential diagnosis of a pelvis mass by 
differentiating uterine from extrauterine causes and it also predicts ovarian 
malignancy in most of the cases. 
 SUMMARY 
 
¾ A prospective study of ovarian tumours was done to assess the diagnostic 
accuracy of Doppler in predicting malignancy. 
¾ The results of this study was based on 50 patients for whom the decision 
had already been made to proceed with operative intervention. 
¾ Incidence of ovarian tumour in my study 4.4%. 
¾ Incidence of malignant tumour was 24% of all ovarian tumours. 
¾ Commonest Benign tumour in my study – serous cystadenoma. Commonest 
malignancy in my study – serous cystadenocarcinoma. 
¾ Doppler showed sensitivity, specificity, positive predictive value of 91.7%, 
94.6% and 84.6% respectively. 
¾ Diagnosis of ovarian tumour is highly accurate with the negative predictive 
value of 97.2%. 
CONCLUSION 
• Prediction of malignancy is of great value  in preoperative evaluation of 
ovarian tumours. 
• Clinical examination the standard diagnostic approach to pelvic mass 
should always be combined with other ancillary aids to the diagnosis. 
• The primary imaging modality in all cases of suspected pelvic mass in 
ultrasonography as it narrows the wider differential diagnosis of pelvic 
tumour. 
• Doppler was highly accurate in predicting the nature of ovarian tumours. 
• Diagnostic accuracy can be improved with CT, MRI. 
• My study on preoperative diagnosis of ovarian tumour with Doppler and 
its correlation with histopathology is simple, safe and reliable. 
• To reduce the mortality of ovarian tumour our aim is to screen all 
postmenopausal women and high risk patient with Doppler and other 
modalities.  
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PROFORMA 
Name :      Age :     I.P.No. 
Occupation: 
Complaints : Abdominal Swelling 
  Abdominal pain 
  Menstrual Disturbances 
  Masculinising Features 
  Postmenopausal bleeding 
  Pressure Symptoms 
  Nonspecific symptoms 
  Asymptomatic 
Menstrual H/o : Early Menarche / Late Menopause 
Marital H/o  : 
Obstetrics H/o. : Nulliparous 
Past H/o.  : H/o Ovulation induction 
   H/o. Oral contraceptive Pill Intake 
   H/o. Breast Lump 
   Gastrointestinal Tumours 
Family H/o. Tumour in relatives.  
O/E 
    GENERAL EXAINATION  Anemia 
     Cachexia 
     Built 
     Nourishment 
     Lymph nodes 
     CVS 
     RS – Pleural effusion 
 P/A    Inspection 
     Palpation 
     Percussion 
 P/S     
 P/V 
 P/R 
 Doppler   Resistance Index 
     Pulsatality Index 
     Low resistance flow 
     High resistance flow 
 Surgery Done  
 Intra operative findings 
 Histopathological Examination   
 
 
 
 
 
 
 
 
 
BENIGN TUMOUR WITH MINIMAL VASCULARITY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MALIGNANCY  WITH LOW RESISTANCE FLOW  
 
S.No. Name Age IPNo. Complaint Mens H Parity GE PA/PV Doppler Laporotomy HPE
1 Kamsala 33 25251 Pain Abd X1 Mth 3/30 P2L2 Fair 
Fullness+ Left -
Formix
No 
Vascularity
Right Ovarian 
Cystectomy
Benign serous 
cystadenoma
2 Lakshmi 40 11010 Pain Lower abdx 8 Mth 3/30
P4 L3 Fair 
P/V Mass of 
10X8 Cm. Felt 
Thro Left Formix
No 
Vascularity
Left Ovarian 
Cystectomy
Benign serous 
cystadenoma
3 Govindammal 45 11788 Pain Abd X1 Mth 3/30 P2L2 Fair 
Mass of 16cm in 
Hypogastric and 
left iliacfossa
High 
resistance 
flow
TAH with LSO  
with rt. Salphingo 
ovariotomy
Benign serous 
cystadenoma
4 Sundari 21 12769 Pain Abd X1 Mth 3/30 Nulli Fair Mass of 18-20WK
No 
Vascularity
Left Ovarian 
Cystectomy
Benign serous 
cystadenoma
5 Philomina 26 12857 Pain Abd X1 Mth 3/30 P2L2 Fair 
Mass of 18-20 
WK
High 
resistance 
flow
Left Ovarian 
Cystectomy
Bengin Cystic 
teratoma 
6 Alima 40 12900 Pain Abd X1 Mth 3/30 P4L4 Anemia
P/V Mass arising 
from Pelvis 
occuping ant and 
lat- fornix
low 
resistance 
flow
TAH with LSO  
with Rt. Salphingo 
ovariotomy
Granulosa cell 
tumour of ovary 
poorly differnetiated
MASTER CHART
7 Sabitha 24 13646
H/O Irregular 
Menstrual Cycle 
+H/o abd. Pain+illiac 
Fossa on and off
3/30 -60 Nulli Fair P/Vleft Fornix + fullness
No 
Vascularity
Laporoscopic Left 
Ovarian 
cystectomy
Chocolate Cyst
8 Uma 28 15403 Bleeding PV x2mth Nulli Fair 
P/V Mass of 
6x6cm. Felt thro 
left fornix.
No 
Vascularity
Left ovariotomy 
with Biopsy form 
right ovary
Bengin Cystic 
teratoma left ovary 
9  Jailakshmi 60 15735
Abd Distension 
X2mth.Abd PainX 
2Mth
3/30 P3L3 Fair 
Irregular Mass 
measuring 20 
Wk. size + 
Ascites
low 
resistance 
flow
Laporotomy with 
B/L Ovariotomy 
with TAH
Serous 
cystadenoma of 
Ovary
10 Panchavarnam 51 16172
Pain abd 1 1/2 
vomiting 2mth on 
and off
3/30 P4L4 Fair 
Post fornix Hard 
Mass
low 
resistance 
flow
B/L 
Ovariantumour 
reduction with 
ifracolic 
omentectomy
Serous 
Cystadenocarcinom
a of Ovary with 
secondary deposits 
in Omentum
11 Gajalakshmi 43 16469 Pain abd 4years
Menopause  
four year 
back
P4L4 Fair 
Mass of 10x8cm. 
In Right iliac and 
hyogastric region
No 
Vascularity
TAH with RSO  
with Lt.  
Ovariotomy
Benign serous 
cystadenoma
12 Jothi 23 16687 Irregular cycles and Dymenorrhoea 5-6/15
P1 L1 Fair 
Mass 5x6cm 
Suprapubically
low 
resistance 
flow
TAH with BSO Kurkenberg Tumour
13 Renuga 51 16925 Abd Swelling x4 Mth Pain abd 4Mth 5/30
P3L3 Fair Mass20x20 Cm
No 
Vascularity
TAH with Rt. 
Salphingo 
Ovariotomy with 
left Salphingo 
oophorectomy
Benign serous 
cystadenoma
14 Krishnaveni 27 18413 Pain abd.X1Mth .H/o Vomiting + 3/30
P2L2 Fair 
P/V Cystic Mass 
of 10x8 Cm. Felt 
ant to Uterus
High 
resistance 
flow
Right Ovarian 
Cystectomy
Benign serous 
cystadenoma
15 Saritha 19 20 Pain abd.1 Mth 3/30 Unmarried Fair 
P/V Mass of 
6x6cm. Felt thro 
left fornix.
No 
Vascularity
Left Ovariotomy 
with Rt. Ovary 
Wedge resection
Benign serous 
cystadenoma
16 Kanakavalli 52 142 Abd Distention 1 Mth 
Attained 
menopause 
11years 
back
P1 L1 Anemia
P/V Vague mass 
present in Right 
ant fornix
low 
resistance 
flow
TAH With BSO 
with omental 
Biopsy
 Mucinous  
CytadenoCarcinom
a
17 Kalavathy 21 605 Pain abd 12Wks 3/30-33 P1 L1 Fair 
P/V mass 
6x6Cm.+ Right 
Fornix 
No 
Vascularity
Right Ovarian 
Cystectomy
Benign serous 
cystadenoma
18 Rukmani 42 907 Pain abd. X6mth 
attained 
menopause 
3years back
P4L4 Fair 
P/V Fullness 
Right fornix
High 
resistance 
flow
Right Ovarian 
Cystectomy
Benign serous 
cystadenoma
19 Bagyathai 55 908 Abd Distention 4mth 
attained 
menopause 
13years 
back
P1 L1 Fair 
Mass Palpable 
up to 28wks
low 
resistance 
flow
TAH With BSO Benign Mucinous Cystadenoma
20 Pramila Devi 38 923 Pain abd.1wks.1day 3/30 P3L3 Fair 
P/V Fullness 
Right fornix
No 
Vascularity TAH With BSO
Benign Serous 
cystadenoma 
21 Radha 48 1981 Pain abd.1.Wk
Attained 
menopause 
1year back
P4 L3 Fair 
Cystic Swelling 
10x6cm.Left iliac 
fossa
No 
Vascularity
Right Ovarian 
Cystectomy
Benign Serous 
Cystadenoma
22 Maliga 40 2612 Pain x 1 yr 3/30 P4L4 Fair Mass of 18wk
low 
resistance 
flow
TAH with  BSO Serous Papillary Cystadenoma
23 Radhika 17 3065
Abd.Swelling 2Mth 
H/O Profuse 
Bleeding 20days
5/30 Unmarried Fair Mass of 24 wks
low 
resistance 
flow
Right ovariotomy 
with omental 
Biopsy and left 
ovarian Biopsy
Yolk Sac Tumour
24 SelvaMary 24 3432 Abd.Swelling 4mth Abd pain 4Mth 5/50 Unmarried Fair 
Mass of 20x10 
Cm
low 
resistance 
flow
Right Ovarian 
Cystectomy
Border Line 
Mucinous tumour 
25 Nalini 42 4886 Pain abd.2 wks 3/30 P1 L1 Fair 
P/V Fullness 
LeftFornix
No 
Vascularity
TAH with RSO  
with Rt.  Ovarian 
Cystectomy 
Benign Mucinous 
Cystadenoma
26 Varalakshmi 38 5135 Pain Abd.1Wks 3/30 P2L2 Fair 
P/Vleft Fornix + 
fullness
No 
Vascularity
Left Salphingo 
Ovariotomy
Benign Serous 
Cystadenoma
27 Rakkammal 41 5350 Abd Swelling x3 Mth Pain abd 3Mth 3/30
P2L2 Anemia Mass of24 wks
High 
resistance 
flow
TAH with Right 
Ovariotomy with 
left Salphingo 
oophorectomy
Beningn Papillary 
Cystadenocarcinom
a
28 Rajeswari 24 5398 Pain  Abd.2Mth 3/30 Nulli Fair P/V Right fornix Fullness+
High 
resistance 
flow
Right ovariotomy Beningn Cystic Teratoma
29 Chandra 47 5976 Pain Abd.7 Mth 3/30-60 P2L2 Fair 
Fullness+ Post 
and Left -Formix
No 
Vascularity
TAH with left 
Ovariotomy with 
RSO
Benign serous 
cystadenoma
30 Shanthi 47 6140 Pain Abd1Mth. Bleeding PV 2days 3/6 months
P3L3 Fair 
P/V Right fornix 
Fullness+
No 
Vascularity
TAH with left 
Ovariotomy with 
RSO
Beingn Serous- 
cyst
31 Sarswathi 35 6361 Irregular Bleeding x1Years. 4/3 Months
P1 L1 Fair 
P/V Right fornix 
Fullness+
High 
resistance 
flow
TAH with left 
Ovariotomy with 
RSO
Benign Serous 
cystadenoma
32 Vijayalashmi 35 6490 Abd Distention X6Mth 3/30 Nulli Fair 
P/V Right fornix 
Fullness+
No 
Vascularity
TAH with Right 
Ovariotomy with 
LSO
Benign serous 
cystadenoma
33 Uma 26 6564 Mass abd.x1year 3/30 P2L2 Fair 
Mass 24-26 wks. 
Size
No 
Vascularity
Left Ovarian 
Cystectomy
Benign serous 
cystadenoma
34 Jayselvi 24 6908 Abd.Distention1Mth 3/30 Nulli Fair Mass of 20Wks.Size
No 
Vascularity
Laporotomy with 
left ovariotomy 
with rigyht ovarian 
wedge  Biospy 
omental Biopsy
Benign Mature 
Cystic Teratoma
35 Vedham 51 7151
Pain Abd.1Mth 
Excessive Bleeding 
Pvx6Wks
6/30 P3L3 Fair 
Mass of 
20Wks.Size
low 
resistance 
flow
Laporotomy with 
debulking of right 
ovary, left 
oophorectomy 
with Hysterectomy
Moderatly 
Differetiated B/L 
Serous 
cystadenocarcinom
a of ovary
36 Bharathi 34 7662 Pain abd 1year 3/30 P2L2 Fair 
P/V Fullness+ 
Right left and ant 
fornix+
High 
resistance 
flow
Right Salphingo 
Ovariotomy
Benign Mucinous 
Cystadenoma
37 Papathi 60 8018 Pain abd 1mth 
Attained 
menopause 
20year back
P6L6 Fair 
P/V Right fornix 
Fullness+
No 
Vascularity
TAH with Right 
Salphingo 
Ovariotomy with 
LSO
Benign Mucinous 
Cystadenoma
38 Lakshmi 44 8057 Pain Abdomen 6mth Mass Abdomen6Mth 6/30
P4 L3 Fair 
Mass of 
22Wks.size
No 
Vascularity
TAH with Right 
Salphingo 
Ovariotomy with 
LSO
Benign serous 
cystadenoma
39 Irfana 18 8232 Pain Abdomen 4mth Mass Abdomen 4Mth 3/30 Unmarried Fair 
Mass of 36Wks. 
Size
low 
resistance 
flow
Left oophorectomy Benign Mucinous Cystadenoma
40 Kulandaiammal 28 8873 Pain abd1year 4/30 P2L2 Fair Mass of 16wks
No 
Vascularity
Right Ovarian 
Cystectomy
Benign serous 
cystadenoma
41 Nisath Begam 14 8990 Abd. Swelling 1Mth 4/30 Unmarried Fair 
Mass of 
7.5x5cm.in left 
iliac fossa
low 
resistance 
flow
Left Ovarian 
Cystectomy Dysgerminoma
42 Shankari 54 91224 Abd Distentionx2Mth
Attained 
menopause 
1year back
P2L3 Fair Mass of24wks
No 
Vascularity
Left Ovarian 
Cystectomy
Benign serous 
cystadenoma
43 Lakshmi 60 9186 Abd.Pain1Mth Distention1Mth
Attained 
menopause 
25year back
P5L5 Fair 
P/V Mass of 
10x8cm. Felt 
through right and 
post fornix
low 
resistance 
flow
Exploratory 
Laporotomy
Papillary serous 
Cystadenocarcinom
a
44 Arupudham 67 9187 Abd.Swelling 1wks Abd.Pain 3wks
Attained 
menopause 
10year back
P5L2 Fair 
Mass of 10x8cm 
Occupying  the 
left iliac fossa
low 
resistance 
flow
TAH with  left 
Salphingo 
ovariotomy
Moderatly 
Differetiated  
Serous 
cystadenocarcinom
a 
45 Shamandishwari 30 9247 Pain abdx3mth 3/30
P5L2 Fair 
Mass of 28wks 
size
No 
Vascularity
Right Ovarian 
Cystectomy
Benign serous 
cystadenoma
46 Kalaivani 48 10016 Pain abd.3 days 5/2-3mts P3L2 Fair 
Mass of 16-18 
wks size
High 
resistance 
flow
Right Ovarian 
Cystectomy
Benign Mucinous 
cystadenoma
47 Kala 17 10273
Pain abdx4Mth 
Difficulty in Passing 
urine 1weeks
3/30 Unmarried Fair 
Mass of 
10x8.8cm.in 
Hypogastric 
region
High 
resistance 
flow
Right Ovarian 
Cystectomy
Benign Mucinous 
Cystadenoma
48 Neela 25 10424 Pain abdx5days 3/30 P2L2 Fair 
Mass of 28 to 
30Wks.Size
High 
resistance 
flow
Right Ovarian 
Cystectomywith 
left ovarian wedge 
biopsy
Benign Mucinous 
Cystadenoma
49 Vanaja 30 10332
Pain abd7 
monthsexcessive 
bleeding 6mths
7/30 P3L3 Fair 
P/V Mass 
of6x5Cm felt in 
ant right fornix
No 
Vascularity
Right ovarian 
Cystectomy
Benign serous 
cystadenoma
50 Malar 22 12006 Pain abdx2Mths 3/30 P3L2 Fair 
Mass of 6x8cm in 
Hypogastric 
region
No 
Vascularity
Right ovarian 
Cystectomy
Benign Serous 
Cystadenoma
6.1%
4.1%
29.0%
2.0%
14.3%
4.1%
20.0%
2.0%
6.1%
12.2%
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
<20 yrs 21-30 yrs 31-40 yrs 41-50 yrs > 50 yrs
AGE DISTRIBUTION OF BENIGN AND MALIGNANT 
OVARIAN TUMOURS
Benign Malignant
MALIGNANT OVARIAN TUMOURS
58.3%
8.3%
8.3%
8.3%
8.3%
8.3%
Serous Mucinous Granulosa
Yolksac Dysgerminoma Krukenberg
8%
17%
50%
25%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
Stage I Stage II Stage III Stage IV
STAGING OF OVARIAN CANCER
BENIGN OVARIAN TUMOURS
65%
21%
11% 3%
Serous Mucinous Dermoid Chocolate
TYPES OF OVARIAN TUMOUR
74%
24%
2%
Benign Malignant Borderline
